Joachim Diebold
Pathologist Computer-Aided Diagnostic Scoring of Tumor Cell Fraction: A Swiss National Study.
Frei A, Oberson R, Baumann E, Perren A, Grobholz R, Lugli A, Dawson H, Abbet C, Lertxundi I, Reinhard S, Mookhoek A, Feichtinger J, Sarro R, Gadient G, Dommann-Scherrer C, Barizzi J, Berezowska S, Glatz K, Dertinger S, Banz Y, Schönegg R, Rubbia-Brandt L, Fleischmann A, Saile G, Mainil-Varlet P, Biral R, Giudici L, Soltermann A, Chaubert A, Stadlmann S, Diebold J, Egervari K, Bénière C, Saro F, Janowczyk A, Zlobec I. Pathologist Computer-Aided Diagnostic Scoring of Tumor Cell Fraction: A Swiss National Study. Mod Pathol 2023; 36:100335.
22.09.2023Pathologist Computer-Aided Diagnostic Scoring of Tumor Cell Fraction: A Swiss National Study.
22.09.2023Mod Pathol 2023; 36:100335
Frei Ana Leni, Oberson Raphaël, Baumann Elias, Perren Aurel, Grobholz Rainer, Lugli Alessandro, Dawson Heather, Abbet Christian, Lertxundi Ibai, Reinhard Stefan, Mookhoek Aart, Feichtinger Johann, Sarro Rossella, Gadient Gallus, Dommann-Scherrer Corina, Barizzi Jessica, Berezowska Sabina, Glatz Katharina, Dertinger Susanne, Banz Yara, Schönegg René, Rubbia-Brandt Laura, Fleischmann Achim, Saile Guenter, Mainil-Varlet Pierre, Biral Ruggero, Giudici Luca, Soltermann Alex, Chaubert Audrey Baur, Stadlmann Sylvia, Diebold Joachim, Egervari Kristof, Bénière Charles, Saro Francesca, Janowczyk Andrew, Zlobec Inti
miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver.
Quintavalle C, Meyer-Schaller N, Roessler S, Calabrese D, Marone R, Riedl T, Picco-Rey S, Panagiotou O, Uzun S, Piscuoglio S, Boldanova T, Bian C, Semela D, Jochum W, Cathomas G, Mertz K, Diebold J, Mazzucchelli L, Koelzer V, Weber A, Decaens T, Terracciano L, Heikenwalder M, Hoshida Y, Andersen J, Thorgeirsson S, Matter M. miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatol Commun 2022; 6:1467-1481.
08.02.2022miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver.
08.02.2022Hepatol Commun 2022; 6:1467-1481
Quintavalle Cristina, Meyer-Schaller Nathalie, Roessler Stephanie, Calabrese Diego, Marone Romina, Riedl Tobias, Picco-Rey Silvia, Panagiotou Orestis A, Uzun Sarp, Piscuoglio Salvatore, Boldanova Tuyana, Bian Chaoran B, Semela David, Jochum Wolfram, Cathomas Gieri, Mertz Kirsten D, Diebold Joachim, Mazzucchelli Luca, Koelzer Viktor H, Weber Achim, Decaens Thomas, Terracciano Luigi M, Heikenwalder Mathias, Hoshida Yujin, Andersen Jesper B, Thorgeirsson Snorri S, Matter Matthias S
NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis
Van Treeck B, Halling K, Hornick J, Diebold J, Loupakis F, Fassan M, Rothermundt C, Stevens T, Torres-Mora J, Thangaiah J, Folpe A. NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Mod Pathol 2021
13.03.2021NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis
13.03.2021Mod Pathol 2021
Van Treeck Benjamin J, Halling Kevin C, Hornick Jason L, Diebold Joachim, Loupakis Fotios, Fassan Matteo, Rothermundt Christian, Stevens Todd M, Torres-Mora Jorge, Thangaiah Judith Jebastin, Folpe Andrew L
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
Savic S, Soltermann A, Zweifel R, Zettl A, von Gunten M, Singer G, Rössle M, Jasarevic Z, Letovanec I, McKee T, Komminoth P, Jochum W, Fleischmann A, Diebold J, Cathomas G, Eppenberger-Castori S, Berezowska S, Bubendorf L. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Arch 2019; 475:67-76.
24.05.2019PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
24.05.2019Virchows Arch 2019; 475:67-76
Savic Spasenija, Soltermann Alex, Zweifel Roland, Zettl Andreas, von Gunten Michael, Singer Gad, Rössle Matthias, Jasarevic Zerina, Letovanec Igor, McKee Thomas, Komminoth Paul, Jochum Wolfram, Fleischmann Achim, Diebold Joachim, Cathomas Gieri, Eppenberger-Castori Serenella, Berezowska Sabina, Bubendorf Lukas
Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing
Zhong Q, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Rogel U, Vassella E, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey J, Wild P. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. Pathol Res Pract 2018; 214:957-963.
22.05.2018Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing
22.05.2018Pathol Res Pract 2018; 214:957-963
Zhong Qing, Diebold Joachim, McKee Thomas, Jochum Wolfram, Kashofer Karl, Hofman Paul, Zischka Melanie, Moch Holger, Rechsteiner Markus, Rogel Uwe, Vassella Erik, Wagner Ulrich, Kurt Henriette, Molinari Francesca, Cathomas Gieri, Komminoth Paul, Barman-Aksözen Jasmin, Schneider-Yin Xiaoye, Rey Jean-Philippe, Wild Peter J
Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients
Mordasini L, Schmid H, Kim S, Muellhaupt G, Engeler D, Mattei A, Diebold J, Diener P, Hechelhammer L, Abt D. Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. J Vasc Interv Radiol 2018; 29:589-597.
23.03.2018Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients
23.03.2018J Vasc Interv Radiol 2018; 29:589-597
Mordasini Livio, Schmid Hans-Peter, Kim Suk-Kyum, Muellhaupt Gautier, Engeler Daniel, Mattei Agostino, Diebold Joachim, Diener Pierre-André, Hechelhammer Lukas, Abt Dominik
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Drilon A, Früh M, Diebold J, Zeidler K, Velcheti V, Riess J, Gandara D, Zalcman G, Froesch P, Michels S, Monnet I, Popat S, Mazières J, Cabillic F, Muley T, Warth A, Shih J, Rothschild S, Karachaliou N, Rosell R, Pall G, Ou S, Yang J, Doebele R, Narayanan V, Camidge R, Owen D, Carbone D, Wolf J, Filleron T, Milia J, Besse B, Remon-Masip J, Jänne P, Mok T, Neal J, Wakelee H, Van Den Heuvel M, Karp D, Byoung C, Peled N, Awad M, Gautschi O. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410.
13.03.2017Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
13.03.2017J Clin Oncol 2017; 35:1403-1410
Drilon Alexander, Früh Martin, Diebold Joachim, Zeidler Kristin, Velcheti Vamsidhar, Riess Jonathan W, Gandara David R, Zalcman Gérard, Froesch Patrizia, Michels Sebastian, Monnet Isabelle, Popat Sanjay, Mazières Julien, Cabillic Florian, Muley Thomas, Warth Arne, Shih Jin-Yuan, Rothschild Sacha I, Karachaliou Niki, Rosell Rafael, Pall Georg, Ou Sai-Hong Ignatius, Yang James C H, Doebele Robert C, Narayanan Vignhesh, Camidge Ross, Owen Dwight, Carbone David P, Wolf Juergen, Filleron Thomas, Milia Julie, Besse Benjamin, Remon-Masip Jordi, Jänne Pasi A, Mok Tony S K, Neal Joel W, Wakelee Heather A, Van Den Heuvel Michael, Karp Daniel D, Byoung Chul-Cho, Peled Nir, Awad Mark M, Gautschi Oliver
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid S, Diebold J, Jochum W, Reichegger H, Klingbiel D, Froesch P, Mark M, Rothschild S, Gautschi O, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2016
19.12.2016Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
19.12.2016J Thorac Oncol 2016
Schmid Sabine, Diebold Joachim, Jochum Wolfram, Reichegger Hermann, Klingbiel Dirk, Froesch Patrizia, Mark Michael, Rothschild Sacha, Gautschi Oliver, Früh Martin
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
01.10.2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
01.10.2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended
Savic S, Kerr K, Bisig B, Tornillo L, Grieshaber S, Baschiera B, Jochum W, Zimmermann A, Diebold J, Bubendorf L. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015; 89:104-9.
21.05.2015Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended
21.05.2015Lung Cancer 2015; 89:104-9
Savic Spasenija, Kerr Keith, Bisig Bettina, Tornillo Luigi, Grieshaber Susanne, Baschiera Betty, Jochum Wolfram, Zimmermann Anne-Katrin, Diebold Joachim, Bubendorf Lukas
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
Varga Z, Viale G, Mastropasqua M, Wagner U, Tapia C, Singer G, Schreiber-Facklam H, Schobinger-Clement S, Sancho Oliver S, Rakozy C, Padberg B, Öhlschlegel C, Obermann E, Noske A, Kaup D, Frick H, Dommann-Scherrer C, Diebold J, Lehr H. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PloS one 2012; 7:e37379.
25.05.2012How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
25.05.2012PloS one 2012; 7:e37379
Varga Zsuzsanna, Viale Giuseppe, Mastropasqua Mauro G, Wagner Urs, Tapia Coya, Singer Gad, Schreiber-Facklam Heide, Schobinger-Clement Sylviane, Sancho Oliver Sara, Rakozy Christiane, Padberg Barbara, Öhlschlegel Christian, Obermann Ellen, Noske Aurelia, Kaup Daniela, Frick Harald, Dommann-Scherrer Corina, Diebold Joachim, Lehr Hans-Anton
Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease
Dambacher J, Lohse P, Ochsenkühn T, Göke B, Diebold J, Otte J, Tillack C, Konrad A, Hofbauer K, Pfennig S, Schnitzler F, Sisic Z, Seiderer J, Staudinger T, Brand S. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13:71-82.
01.01.2007Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease
01.01.2007Inflamm Bowel Dis 2007; 13:71-82
Dambacher Julia, Lohse Peter, Ochsenkühn Thomas, Göke Burkhard, Diebold Joachim, Otte Jan-Michel, Tillack Cornelia, Konrad Astrid, Hofbauer Katrin, Pfennig Simone, Schnitzler Fabian, Sisic Zeljka, Seiderer Julia, Staudinger Tanja, Brand Stephan
Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy
Seiderer J, Zech C, Diebold J, Schoenberg S, Brand S, Tillack C, Göke B, Ochsenkühn T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553-5.
01.05.2006Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy
01.05.2006Eur J Gastroenterol Hepatol 2006; 18:553-5
Seiderer Julia, Zech Christoph J, Diebold Joachim, Schoenberg Stefan O, Brand Stephan, Tillack Cornelia, Göke Burkhard, Ochsenkühn Thomas
Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells
Brand S, Olszak T, Beigel F, Diebold J, Otte J, Eichhorst S, Göke B, Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem 2006; 97:709-23.
01.03.2006Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells
01.03.2006J Cell Biochem 2006; 97:709-23
Brand Stephan, Olszak Torsten, Beigel Florian, Diebold Joachim, Otte Jan-Michel, Eichhorst Soeren T, Göke Burkhard, Dambacher Julia
CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation
Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte J, Göke B, Eichhorst S. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005; 310:117-30.
15.10.2005CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation
15.10.2005Exp Cell Res 2005; 310:117-30
Brand Stephan, Dambacher Julia, Beigel Florian, Olszak Torsten, Diebold Joachim, Otte Jan-Michel, Göke Burkhard, Eichhorst Sören T
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression
Brand S, Göke B, Auernhammer C, Adler B, Diepolder H, Diebold J, Otte J, Eichhorst S, Zitzmann K, Olszak T, Beigel F, Dambacher J. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289:G960-8.
28.07.2005IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression
28.07.2005Am J Physiol Gastrointest Liver Physiol 2005; 289:G960-8
Brand Stephan, Göke Burkhard, Auernhammer Christoph J, Adler Barbara, Diepolder Helmut, Diebold Joachim, Otte Jan-Michel, Eichhorst Sören T, Zitzmann Kathrin, Olszak Torsten, Beigel Florian, Dambacher Julia